Knowledge center

The place to find all the most innovative research and information on novel biologics and biosimilars.

Press Releases

Polpharma Biologics Group announces that its joint venture company, Bioeq, has entered into a commercialization agreement for biosimilar Ranibizumab

The reference product is a monoclonal anti-angiogenic antibody fragment (Fab) that has been approved to treat the "wet" type of age-related macular degeneration, a common form of age-related vision loss.


You can find all the latest presentations, brochures and fact sheets below covering our solutions and portfolio.

Let’s collaborate and create quality biologics together.

Get in touch for more information.